Curanex Pharmaceuticals Inc Common Stock (CURX) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-44.2%

$3.26

vs $5.85 price

Levered DCF

$3.26

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

10.38

Safe zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022
P/E	-2.22×	-309.23×	-5,826.09×	-5,506.85×
P/B	0.83×	221.62×	1,856.47×	0×
P/S	0×	0×	0×	4,290.58×
EV / EBITDA	-1.15×	-383.65×	-6,376.52×	0×
Gross margin	0.0%	0.0%	0.0%	17.0%
Operating margin	0.0%	0.0%	0.0%	-77.8%
Net margin	0.0%	0.0%	0.0%	-77.8%
Current ratio	81.93×	35.54×	5.21×	0×
Debt / equity	0.03×	0×	0×	0×
Interest coverage	-496.55×	0×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022
Return on equity	-37.7%	-71.8%	-31.9%	0.0%
Return on invested capital	-36.7%	-72.5%	-32.1%	0.0%
Return on assets	-36.5%	-69.8%	-25.8%	0.0%
Free cash flow yield	-111.9%	-0.5%	-0.0%	0.0%
Earnings yield	-45.1%	-0.3%	-0.0%	-0.0%
Enterprise value	$4.7M	$111.4M	$111.5M	$0
Net debt / EBITDA	1.12×	0.51×	4.25×	0×
Cash conversion cycle (days)	0	0	0	0